The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 28 March 2006, www.theannals.com, DOI 10.1345/aph.1G295.
This Article
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stumpf, J. L
Right arrow Articles by Patel, A. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stumpf, J. L
Right arrow Articles by Patel, A. C


ARTICLES

Safety of Angiotensin-Converting Enzyme Inhibitors in Patients with Insect Venom Allergies (April)

Janice L Stumpf PharmD1, Nadine Shehab PharmD2*, Anish C Patel PharmD3

1 Clinical Pharmacist, Drug Information Service; Clinical Associate Professor, University of Michigan Health System and College of Pharmacy, Ann Arbor, MI
2 Clinical Pharmacist, Drug Information Service; Clinical Assistant Professor, University of Michigan Health System and College of Pharmacy
3 at time of writing, PharmD Student, College of Pharmacy, University of Michigan; now, Post-Doctoral Pharmaceutical Industry Fellow, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ

* To whom correspondence should be addressed. E-mail: nshehab{at}umich.edu.


   Abstract

OBJECTIVE: To review the literature with respect to the safety of angiotensin-converting enzyme (ACE) inhibitors in patients allergic to insect venom and those undergoing venom immunotherapy (VIT).

DATA SOURCES: A MEDLINE search was conducted (1966-March 2006) using the following search terms: bee sting, venom, insect stings, ACE inhibitors, angiotensin II receptor blockers, immunotherapy, and desensitization. The bibliographies of qualifying articles were also searched for relevant references.

DATA SYNTHESIS: Several case reports have described severe allergic reactions, including anaphylaxis, in patients taking ACE inhibitors subsequent to being stung or receiving VIT. Exacerbation of the allergic response by ACE inhibitors is thought to be related to accumulation of bradykinin and inhibition of the formation of angiotensin II. Similar reactions have not been described with angiotensin-receptor blockers, but are theoretically possible.

CONCLUSIONS: ACE inhibitors may exacerbate the response to insect venom, resulting in potentially life-threatening allergic reactions to insect stings or VIT. Although this risk is difficult to quantify based only on data from case reports, it seems prudent that patients with documented allergic reactions to insect venom avoid ACE inhibitor therapy, if possible. If, after careful consideration of the risks and benefits, ACE inhibitor therapy is deemed warranted, education regarding measures to minimize exposure to insect stings and training on self-administration of epinephrine should be provided, as with any person with venom allergy. In patients in whom VIT is appropriate, temporary discontinuation of the ACE inhibitor prior to each venom injection may prevent subsequent adverse reactions.

Key Words: anaphylaxis, angiotensin-converting enzyme inhibitors, venom immunotherapy.

Reprints: Dr. Shehab, University of Michigan Health System, UH B2D301 Box 0008, 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0008, fax 734/936-7027, nshehab@umich.edu







homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.